研究業績

研究業績

論文業績

  1. Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Sci Rep. 2019;9:13362
  2. Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H, Tokunaga S, Shimokawa M, Ito Y, Saeki T. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer. 2019 Aug 12. doi: 10.1007/s12282-019-01001-1. [Epub ahead of print]
  3. Haratake N, Seto T, Takamori S, Toyozawa R, Nosaki K, Miura N, Ohba T, Toyokawa G, Taguchi K, Yamaguchi M, Shimokawa M, Takenoyama M. Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thorac Cancer. 2019;10:1779-1787.
  4. Yamashita YI, Hayashi H, Imai K, Okabe H, Nakagawa S, Kitamura F, Uemura N, Nakao Y, Yusa T, Itoyama R, Yamao T, Umesaki N, Miyata T, Chikamoto A, Shimokawa M, Baba H. Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. World J Surg. 2019;43:2894-2901.
  5. Yoshida I, Tamura K, Miyamoto T, Shimokawa M, Takamatsu Y, Nanya Y, Matsumura I, Gotoh M, Igarashi T, Takahashi T, Aiba K, Kumagai K, Ishizawa K, Kurita N, Usui N, Hatake K. Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan. In Vivo. 2019;33:1355-1362.
  6. Kurozumi A, Okada Y, Shimokawa M, Goshima Y, Otsuka T, Narisawa M, Torimoto K, Tanaka Y. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor. Diabetes Technol Ther. 2019;21:385-392.
  7. Takada K, Shimokawa M, Tanaka K, Kohashi K, Haro A, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Oda Y, Mori M. Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. PLoS One. 2019;14:e0217991.
  8. Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). Int J Clin Oncol. 2019;24:1223-1230.
  9. Shimamatsu S, Takenoyama M, Shimokawa M, Takada K, Edagawa M, Toyozawa R, Nosaki K, Oba T, Tagawa T, Yamaguchi M, Taguchi K, Seto T. The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer. Ann Thorac Surg. 2019;108:1080-1086.
  10. Matsubara T, Tagawa T, Takada K, Toyokawa G, Shimokawa M, Kozuma Y, Akamine T, Haro A, Osoegawa A, Mori M. Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis. Clin Lung Cancer. 2019;20:e504-e513.
  11. Matsubara T, Toyokawa G, Takada K, Kinoshita F, Kozuma Y, Akamine T, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Mori M. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma. PLoS One. 2019;14:e0215103.
  12. Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y. A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. J Thorac Dis. 2019;11:927-935.
  13. Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S. Significance of the Red Blood Cell Distribution Width in Resected Pathologic Stage I Nonsmall Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2019 Apr 19. pii: S1043-0679(19)30134-0. doi: 10.1053/j.semtcvs.2019.04.011. [Epub ahead of print]
  14. Takada K, Shimokawa M, Akamine T, Ono Y, Haro A, Osoegawa A, Tagawa T, Mori M. Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer. Anticancer Res. 2019;39:1987-1996.
  15. Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Ann Surg Oncol. 2019;26:1916-1924.
  16. Takada K, Kohashi K, Shimokawa M,Haro A,Osoegawa A, Tagawa T, Seto T, Oda Y, Maehara Y. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. Lung Cancer. 2019;128:26-32.
  17. Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y. The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers. Interact Cardiovasc Thorac Surg. 2019;28:735-743.
  18. Shimokawa M, Hayashi T, Kogawa T, Matsui R, Mizuno M, Kikkawa F, Saeki T, Aiba K, Tamura K. Evaluation of combination antiemetic therapy on CINV in patients with gynecologic cancer receiving TC chemotherapy. Anticancer Res. 2019;39:225-230.
  19. Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y. A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas. Ann Thorac Surg. 2019;107:393-400.
  20. Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41-49.
  21. Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K, Kusumoto T, Munemoto Y, Nakanishi R, Nakashima Y, Saeki H, Maehara Y. Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial. Surgery. 2019;165:586-592.
  22. Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res. 2018;10:4249-4255.
  23. Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018;38:5897-5901.
  24. Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. Lung Cancer. 2018;124:255-259.
  25. Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y. Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study. Anticancer Res. 2018;38:5295-5303.
  26. Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018;9:32321-32330.
  27. Nishio S, Shimokawa M, Tasaki K, Nasu H, Yoshimitsu T, Matsukuma K, Terada A, Tsuda N, Kawano K, Ushijima K. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis. Gynecol Oncol. 2018;150:432-437.
  28. Yamamoto M, Shimokawa M, Kawano H, Ohta M, Yoshida D, Minami K, Ikebe M, Morita M, Toh Y. Benefits of laparoscopic surgery compared to open standard surgery for gastric carcinoma in elderly patients: propensity score-matching analysis. Surg Endosc. 2019;33:510-519.
  29. Nishio S, Aihara S, Shimokawa M, Fujishita A, Taniguchi S, Hachisuga T, Yanazume S, Kobayashi H, Murakami F, Numa F, Kotera K, Okura N, Toki N, Yokoyama M, Ushijima K. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131). J Gynecol Oncol. 2018;29:e77.
  30. Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. Eur J Cancer. 2018;101:20-29.
  31. Toyokawa G, Yamada Y, Tagawa T, Kamitani T, Yamasaki Y, Shimokawa M, Oda Y, Maehara Y. Computed tomography features of resected lung adenocarcinomas with spread through air spaces. J Thorac Cardiovasc Surg. 2018;156:1670-1676.e4.
  32. Shoji F, Takeo S, Yamazaki K, Miura N, Katsura M, Oku Y, Shimokawa M. Impact of Preoperative Ultrasonography Screening for Carotid Artery Stenosis in Lung Cancer Patients. Ann Thorac Surg. 2018;106:1047-1054.
  33. Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Honda H, Maehara Y. Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation. Anticancer Res. 2018;38:3731-3734.
  34. Takamori S, Tagawa T, Toyokawa G, Ueo H, Shimokawa M, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Akamine T, Katsura M, Takada K, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y. The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis. Cancer Med. 2018 May 29. doi: 10.1002/cam4.1539. [Epub ahead of print]
  35. Miyata T, Yamashita YI, Baba Y, Harada K, Yamao T, Umezaki N, Tsukamoto M, Kitano Y, Yamamura K, Arima K, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Shimokawa M, Baba H. Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget. 2018;9:20795-20806.
  36. Yano T, Shimokawa M, Kawashima O, Takenoyama M, Yamashita Y, Fukami T, Ueno T, Yatsuyanagi E, Fukuyama S; National Hospital Organization Network Collaborative Research—Thoracic Oncology Group. The influence of comorbidity on the postoperative survival in elderly (≥ 75 years old) with lung cancer. Gen Thorac Cardiovasc Surg. 2018;66:344-350.
  37. Takekuma M, Shimokawa M, Nishio S, Omi H, Tabata T, Takei Y, Nasu K, Takahashi Y, Toyota S, Ichikawa Y, Arakawa A, Ito F, Tsubamoto H, Mori T, Hirashima Y, Ito K. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis. Cancer Sci. 2018;109:1602-1608.
  38. Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surg Oncol. 2018;27:88-94.
  39. Tanioka H, Miyamoto Y, Tsuji A, Asayama M, Shiraishi T, Yuki S, Kotaka M, Makiyama A, Shimokawa M, Shimose T, Masuda S, Yamaguchi T, Komatsu Y, Saeki H, Emi Y, Baba H, Oki E, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). Oncology. 2018;94:289-296.
  40. Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Seto T, Tagawa T, Takenoyama M, Ichinose Y, Maehara Y. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study. Ann Surg Oncol. 2018;25:1555-1563.
  41. Takada K, Toyokawa G, Tagawa T, Kohashi K, Shimokawa M, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer. 2018;116:1-6.
  42. Shimokawa M, Kogawa T, Shimada T, Saito T, Kumagai H, Ohki M and Kaku T. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872-879.
  43. Suyama K, Tomiguchi M, Takeshita T, Sueta A, Yamamoto-Ibusuki M, Shimokawa M, Yamamoto Y, Iwase H. Factors involved in early lenvatinib dose reduction: a retrospective analysis. Med Oncol. 2018;35:19.
  44. Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer. 2018;21:792-801.
  45. Takamori S, Toyokawa G, Okamoto T, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takada K, Katsura M, Hirai F, Shoji F, Tagawa T, Oda Y, Honda H, Maehara Y. Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. Ann Surg Oncol. 2018;25:1229-1236.
  46. Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes Metab. 2018;20:1311-1315.
  47. Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, Akagi Y, Sakamoto Y, Tanaka T, Saeki H, Maehara Y, Baba H. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer. Anticancer Res. 2018;38:491-499.
  48. Okadome M, Saito T, Kitade S, Ariyoshi K, Shimamoto K, Kawano H, Minami K, Nakamura M, Shimokawa M, Okushima K, Kubo Y, Kunitake N. Renal function and urological complications after radical hysterectomy with postoperative radiotherapy and platinum-based chemotherapy for cervical cancer. Jpn J Clin Oncol. 2018;48:115-123.
  49. Korehisa S, Oki E, Iimori M, Nakaji Y, Shimokawa M, Saeki H, Okano S, Oda Y, Maehara Y. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Int J Cancer. 2018;142:822-832.
  50. Toyokawa G, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Takada K, Katsura M, Shoji F, Okamoto T, Maehara Y. Invasive features of small-sized lung adenocarcinoma adjoining emphysematous bullae. Eur J Cardiothorac Surg. 2018;53:372-378.
  51. Furubayashi N, Negishi T, Yamashita T, Kusano S, Taguchi K, Shimokawa M, Nakamura M. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Mol Clin Oncol. 2017;7:1112-1118.
  52. Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Takada K, Katsura M, Shimokawa M, Shoji F, Okamoto T, Maehara Y. Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. J Thorac Dis. 2017;9:2942-2951.
  53. Arai H, Hironaka S, Minashi K, Denda T, Shimokawa M, Yamaguchi T. Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer. Jpn J Clin Oncol. 2017;47:942-948.
  54. Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M. Erratum to: Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial. Surg Today. 2017;47:1539-1540.
  55. Morokuma S, Shimokawa M, Kato K, Sanefuji M, Shibata E, Tsuji M, Senju A, Kawamoto T, Kusuhara K; Japan Environment & Children's Study Group. Maternal sleep and small for gestational age infants in the Japan Environment and Children's Study: a cohort study. BMC Res Notes. 2017;10:394.
  56. Furubayashi N, Negishi T, Yamashita T, Kusano S, Taguchi K, Shimokawa M, Nakamura M. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol. 2017;7:454-460.
  57. Fujishita T, Okamoto T, Akamine T, Takamori S, Takada K, Katsura M, Toyokawa G, Shoji F, Shimokawa M, Oda Y, Nakabeppu Y, Maehara Y. Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer. Lung Cancer. 2017;109:52-57.
  58. Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). Int J Clin Oncol. 2017;22:913-920.
  59. Furubayashi N, Negishi T, Iwai H, Nagase K, Taguchi K, Shimokawa M, Nakamura M. Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy. Mol Clin Oncol. 2017;6:775-781.
  60. Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, Hino R, Hanada S, Jo T, Tsukasaki K, Moriuchi Y, Sueoka E, Yoshida S, Suzushima H, Miyahara M, Yamashita K, Eto T, Suzumiya J, Tamura K. A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39-47.
  61. Tsuji Y, Baba H, Takeda K, Kobayashi M, Oki E, Gotoh M, Yoshida K, Shimokawa M, Kakeji Y, Aiba K. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18:753-758.
  62. Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, Yano H, Mashino K, Mitsuyama S, Shimokawa M, Tamura K; Kyushu Breast Cancer Study Group. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast. 2017;32:66-72.
  63. Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2707-2714.
  64. Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer. 2017;18:572-582.
  65. Shimada T, Saito T, Shimokawa M, Shimamoto K, Matsushita S, Yamaguchi S, Ariyoshi K, Okadome M. Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy. Jpn J Clin Oncol. 2017;47:494-498
  66. Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). Cancer Chemother Pharmacol. 2017;79:147-153.
  67. Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol. 2017;22:405-412.
  68. Miyashita K, Fujii K, Taguchi K, Shimokawa M, Yoshida MA, Abe Y, Okamura J, Oda S, Uike N. A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients. J Cancer Res Clin Oncol. 2017;143:399–408.
  69. Baba Y, Baba H, Ishihara R, Shimada H, Noguchi T, Miyazaki T, Yoshikawa T, Nakajima Y, Tsuji Y, Shimokawa M, Kitagawa Y, Aiba K. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Diseases of the Esophagus. 2017;30:1-7.
  70. Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y. The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma. Anticancer Research. 2016;36:4841-4846.
  71. Morokuma S, Shimokawa M, Kato K, Sanefuji M, Shibata E, Tsuji M, Senju A, Kawamoto T, Kusuhara K; Japan Environment & Children's Study Group. Relationship between hyperemesis gravidarum and small-for-gestational-age in the Japanese population: the Japan Environment and Children's Study (JECS). BMC Pregnancy and Childbirth. 2016;16:247.
  72. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016;7:58492-58499.
  73. Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemother Pharmacol. 2016;78:585-93.
  74. Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, Morodomi Y, Okano S, Oda Y, Maehara Y. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. J Thorac Oncol. 2016;11:1879-1890.
  75. Furubayashi N, Negishi T, Ura S, Mutaguchi J, Taguchi K, Shimokawa M, Nakamura M. Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence. Oncology Letters. 2016;11:3882-3888.
  76. Tanakaya K, Yamaguchi T, Ishikawa H, Hinoi T, Furukawa Y, Hirata K, Saida Y, Shimokawa M, Arai M, Matsubara N, Tomita N, Tamura K, Sugano K, Ishioka C, Yoshida T, Ishida H, Watanabe T, Sugihara K; for HNPCC Registry and Genetic Testing Project of the Japanese Society for Cancer of the Colon and Rectum. Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome. Anticancer Research. 2016;36:1985-1989.
  77. Nitta H, Baba H, Sugimori K, Furuse J, Ohkawa S, Yamamoto K, Minami H, Shimokawa M, Wakabayashi G, Aiba K; CINV Study Group of Japan. Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan. Anticancer Research. 2016;36:1929-1935.
  78. Iwanaga A, Egashira A,Minami K, Saeki H, Yamamoto M, Morita M, Seto T, Takenoyama M, Ueda M, Okushima K, Shimokawa M, Toh Y, Okamura T. Evaluation of esophageal and airway stent placement for patients with advanced and recurrent esophageal cancer. Esophagus. 2016;13:283-289.
  79. Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N, Narahara H, Aoki D, Kimura E, Kato H, Shimokawa M, Sugiyama T, Kamura T. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. Gynecologic Oncology. 2016;140:559-564.
  80. Miyamoto Y, Tsuji A, Tanioka H, Maekawa S, Kawanaka H, Kitazono M, Oki E, Emi Y, Murakami H, Ogata Y, Saeki H, Shimokawa M, Natsugoe S, Akagi Y, Baba H, Maehara Y. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). International Journal of Clinical Oncology. 2016;21:705-712.
  81. Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. International Journal of Clinical Oncology. 2016;21:491-497.
  82. Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, Sadanaga N, Kusumoto T, Touyama T, Kimura M, Baba H, Akagi Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). International Journal of Clinical Oncology. 2016;21:335-343.
  83. Eto T, Zhao Y, Maruyama A, Miyashita K, Yasui A, Nakao S, Taguchi K, Shimokawa M, Oda S, Saito T. Modal variety of microsatellite instability in human endometrial carcinomas. Journal of Cancer Research and Clinical Oncology. 2016;142:353-363.
  84. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, Shimokawa M, Kawai K, Suzumiya J, Tamura K. Treatment and survival among 1594 patients with ATL diagnosed in the 2000s: a report from the ATL-PI project performed in Japan. Blood. 2015;126:2570-2577.
  85. Ohmaru T, Fujita Y, Sugitani M, Shimokawa M, Fukushima K, Kato K. Placental elasticity evaluation using virtual touch tissue quantification during pregnancy. Placenta. 2015;36:915-920.
  86. Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncology Letters. 2015;9:2577-2582.
  87. Kogawa T, Doi A, Shimokawa M, Fouad TM, Osuga T, Tamura F, Mizushima T, Kimura T, Abe S, Ihara H, Kukitsu T, Sumiyoshi T, Yoshizaki N, Hirayama M, Sasaki T, Kawarada Y, Kitashiro S, Okushiba S, Kondo H, Tsuji Y. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Targeted Oncology. 2015;10:125-133.
  88. Aso T, Matsuo M, Kiyohara H, Taguchi K, Rikimaru F, Shimokawa M, Segawa Y, Higaki Y, Umeno H, Nakashima T, Masuda M. Induction of CD44 Variant 9-Expressing Cancer Stem Cells Might Attenuate the Efficacy of Chemoradioselection and Worsens the Prognosis of Patients with Advanced Head and Neck Cancer. PLoS One. 2015;10:e0116596.
  89. Takenaka T, Takenoyama M, Yamaguchi M, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Yoshida T, Shiraishi Y, Morodomi Y, Hirai F, Taguchi K, Shimokawa M, Seto T, Ichinose Y. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. European Journal Cardio-Thoracic Surgery. 2015;47:550-555.
  90. Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M; CINV Study Group of Japan. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. International Journal of Clinical Oncology. 2015;20:855-865.
  91. Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 2015;88:52-56.
  92. Matsumoto I, Tanaka M, Shirakawa S, Shinzeki M, Toyama H, Asari S, Goto T, Yamashita H, Ishida J, Ajiki T, Fukumoto T, Shimokawa M, Ku Y. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology. 2015;22:2408-2415.
  93. Shimokawa M, Ohki M, Kaku T. Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2015;36:370-375.
  94. Furubayashi N, Negishi T, Hirata Y, Taguchi K, Shimokawa M, Nakamura M. Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy. Oncology Letters. 2014;8:2237-2242.
  95. Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. International Journal of Hematology. 2014;100:386-392.
  96. Kohno M, Okamoto T, Suda K, Shimokawa M, Kitahara H, Shimamatsu S, Konishi H, Yoshida T, Takenoyama M, Yano T, Maehara Y. Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR mutations. Clinical Cancer Research. 2014;20:3613-3622.
  97. Oki E, Emi Y, Kusumoto T, Sakaguchi Y, Yamamoto M, Sadanaga N, Shimokawa M, Yamanaka T, Saeki H, Morita M, Takahashi I, Hirabayashi N, Sakai K, Orita H, Aishima S, Kakeji Y, Yamaguchi K, Yoshida K, Baba H, Maehara Y. Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. Annals of Surgical Oncology. 2014;21:2340-2346.
  98. Hirai F, Seto T, Shimokawa M, Inamasu E, Toyozawa R, Toyokawa G, Yoshida T, Shiraishi Y, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y. Split-dose Cisplatin and Vinorelbine as Adjuvant Chemotherapy for Completely Resected Non-small Cell Lung Cancer. Anticancer Research. 2014;34:927-931.
  99. Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Maeno K, Saeki S, Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer. Japanese Journal of Clinical Oncology. 2014;44:127-133.
  100. Shimamoto K, Saito T, Okadome M, Shimokawa M. Prognostic significance of the treatment-free interval in patients with recurrent endometrial cancer. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2014;175:92-96.
  101. Fujiwara A, Fukushima K, Inoue H, Takashima T, Nakahara H, Satoh S, Ochiai M, Hara T, Shimokawa M, Kato K. Perinatal management of preterm premature ruptured membranes affects neonatal prognosis. Journal of Perinatal Medicine. 2014;42:499-505.
  102. Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. International Journal of Clinical Oncology. 2014;19:601-606.
  103. Inagaki J, Fukano R, Kodama Y, Nishimura M, Shimokawa M, Okamura J. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. Annals of Hematology. 2014;93:645-651.
  104. Saeki H, Emi Y, Kumashiro R, Otsu H, Kawano H, Ando K, Ida S, Kimura Y, Tokunaga E, Oki E, Morita M, Shimokawa M, Maehara Y. Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. Surgery Today. 2014;44:1457-1464.
  105. Eto T, Saito T, Shimokawa M, Hatae M, Takeshima N, Kobayashi H, Kasamatsu T, Yoshikawa H, Kamura T, Konishi I. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: A retrospective multi-institutional study of 426 patients in Japan. Gynecologic Oncology. 2013;131:574-580.
  106. Sugitani M, Fujita Y, Yumoto Y, Fukushima K, Takeuchi T, Shimokawa M, Kato K. A new method for measurement of placental elasticity: Acoustic radiation force impulse imaging. Placenta. 2013;34:1009-1013.
  107. Toyokawa G, Takenoyama M, Taguchi K, Toyozawa R, Inamasu E, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Seto T, Shimokawa M, Ichinose Y. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer. 2013;81:487-490.
  108. Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M, Yoshida K, Onimaru M, Onohara T, Inoguchi H, Kyuragi R, Guntani A, Shimokawa M, Ban H, Tanaka M, Inoue M, Shu T, Hasegawa M, Nakanishi Y, Maehara Y. DVC1-0101 to treat peripheral arterial disease : A Phase I/IIa open-label dose-escalation clinical trial. Molecular Therapy. 2013;21:707-714.